Patents by Inventor Rohan Rej

Rohan Rej has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Imidazo[4,5-c]pyridine compounds as LSD-1 inhibitors
    Patent number: 11944614
    Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, and R4 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to LSD1 inhibition such as cancer.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: April 2, 2024
    Assignee: REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Rohan Rej
  • Cereblon Ligands and Uses Thereof
    Publication number: 20240059704
    Abstract: Described herein are compounds or conjugates of of Formulae II and I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading certain proteins).
    Type: Application
    Filed: July 12, 2023
    Publication date: February 22, 2024
    Inventors: Shaomeng Wang, Zhixiang Chen, Dimin Wu, Ranjan Kumar Acharyya, Weiguo Xiang, Rohan Rej, Longchuan Bai, Xuqing Zhang, Guozhang Xu
  • Cereblon Ligands and Uses Thereof
    Publication number: 20240059711
    Abstract: Described herein are compounds of Formula I and conjugates of Formula I? and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading certain proteins).
    Type: Application
    Filed: July 12, 2023
    Publication date: February 22, 2024
    Inventors: Shaomeng Wang, Zhixiang Chen, Dimin Wu, Yuk-Ming Siu, Rohan Rej, Ranjan Kumar Acharyya, Weiguo Xiang, Longchuan Bai
  • ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND
    Publication number: 20230357249
    Abstract: The present disclosure provides compounds represented by Formula I : A-L-B 1 I, and the salts or solvates thereof, wherein A, L, and B1 are as defined in the specification, ompounds having Formula I are androgen receptor degraders useful for the treatment of ancer and other diseases.
    Type: Application
    Filed: May 14, 2021
    Publication date: November 9, 2023
    Inventors: Shaomeng Wang, Xin Han, Weiguo Xiang, Chong Qin, Tianfeng Xu, Lijie Zhao, Mingliang Wang, Rohan Rej
  • MDM2 PROTEIN DEGRADERS
    Publication number: 20220411432
    Abstract: The present disclosure provides compounds represented by Formula I-A: A1-L1-B1??I-A and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein A1, B1, and L1 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a condition or disorder responsive to degradation of MDM2 protein such as cancer.
    Type: Application
    Filed: August 31, 2021
    Publication date: December 29, 2022
    Inventors: Shaomeng Wang, Yangbing Li, Jiuling Yang, Angelo Aguilar, Bing Zhou, Jiantao Hu, Fuming Xu, Rohan Rej, Xin Han
  • CEREBLON E3 LIGASE INHIBITORS
    Publication number: 20220388978
    Abstract: The present disclosure provides compounds represented by Formula I: wherein R2a, R2b, R2c, R2d, R3, R13, and Z are as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are cereblon (CRBN) ubiquitination inhibitors or monofunctional synthetic intermediates that can be used to prepare PROTAC molecules. CRBN ubiquitination inhibitors and PROTAC molecules are useful for the treatment of cancer and other diseases.
    Type: Application
    Filed: August 27, 2020
    Publication date: December 8, 2022
    Inventors: Shaomeng Wang, Tianfeng Xu, Mingliang Wang, Jiantao Hu, Xi Han, Weiguo Xiang, Rohan Rej
  • IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF
    Publication number: 20220227778
    Abstract: The present disclosure provides compounds represented by Formula I: wherein R1, R2, R3, and R4 are as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are EED inhibitors. EED inhibitors are useful for the treatment of cancer and other diseases.
    Type: Application
    Filed: July 16, 2020
    Publication date: July 21, 2022
    Inventors: Shaomeng Wang, Rohan Rej, Changwei Wang, Mi Wang, Jianfeng Lu, Chao-Yie Yang, Ester Fernandez-Salas, Jeanne Stuckey
  • MDM2 protein degraders
    Patent number: 11192898
    Abstract: The present disclosure provides compounds represented by Formula I-A: A1-L1-B1 I-A and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein A1, B1, and L1 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a condition or disorder responsive to degradation of MDM2 protein such as cancer.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: December 7, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Yangbing Li, Jiuling Yang, Angelo Aguilar, Bing Zhou, Jiantao Hu, Fuming Xu, Rohan Rej, Xin Han
  • IMIDAZO[4,5-C]PYRIDINE COMPOUNDS AS LSD-1 INHIBITORS
    Publication number: 20210236474
    Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, and R4 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to LSD1 inhibition such as cancer.
    Type: Application
    Filed: May 13, 2019
    Publication date: August 5, 2021
    Inventors: Shaomeng Wang, Rohan Rej
  • MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION
    Publication number: 20210002289
    Abstract: The present disclosure provides compounds represented by Formula I: and the salts or solvates thereof, wherein X, L, Y, and B are as defined in the specification. Compounds having Formula I are immunomodulators and/or monofunctional synthetic intermediates that can be used to prepare small-molecule drug conjugates.
    Type: Application
    Filed: August 31, 2020
    Publication date: January 7, 2021
    Inventors: Yangbing Li, Angelo Aguilar, Bing Zhou, Jiantao Hu, Fuming Xu, Chong Qin, Yang Hu, Weiguo Xiang, Rohan Rej, Jiuling Yang, Xin Han, Longchuan Bai, Chao-Yie Yang
  • Monofunctional intermediates for ligand-dependent target protein degradation
    Patent number: 10759808
    Abstract: The present disclosure provides compounds represented by Formula I: and the salts or solvates thereof, wherein X, L, Y, and B are as defined in the specification. Compounds having Formula I are immunomodulators and/or monofunctional synthetic intermediates that can be used to prepare small-molecule drug conjugates.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: September 1, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Yangbing Li, Angelo Aguilar, Bing Zhou, Jiantao Hu, Fuming Xu, Chong Qin, Yang Hu, Weiguo Xiang, Rohan Rej, Jiuling Yang, Xin Han, Longchuan Bai, Chao-Yie Yang
  • MDM2 PROTEIN DEGRADERS
    Publication number: 20190127387
    Abstract: The present disclosure provides compounds represented by Formula I-A: A1-L1-B1 I-A and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein A1, B1, and L1 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a condition or disorder responsive to degradation of MDM2 protein such as cancer.
    Type: Application
    Filed: April 6, 2017
    Publication date: May 2, 2019
    Inventors: Shaomeng Wang, Yangbing Li, Jiuling Yang, Angelo Aguilar, Bing Zhou, Jiantao Hu, Fuming Xu, Rohan Rej, Xin Han
  • MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION
    Publication number: 20190119289
    Abstract: The present disclosure provides compounds represented by Formula I: and the salts or solvates thereof, wherein X, L, Y, and B are as defined in the specification. Compounds having Formula I are immunomodulators and/or monofunctional synthetic intermediates that can be used to prepare small-molecule drug conjugates.
    Type: Application
    Filed: April 6, 2017
    Publication date: April 25, 2019
    Inventors: Shaomeng Wang, Yangbing Li, Angelo Aguilar, Bing Zhou, Jiantao Hu, Fuming Xu, Chong Qin, Yang Hu, Weiguo Xiang, Rohan Rej, Jiuling Yang, Xin Han, Longchuan Bai, Chao-Yie Yang